

Every year, scientists from across the country gather for Canadian Conference on HIV/AIDS Research (CAHR). This year it…

Dr. Paolo Palma joined the CTN+ in 2025 as a postdoctoral fellow. Grounded by a background in social…

Today, the HIV research community is one step closer to finding a cure. In a Canadian first, a…
Randomized Trial to Prevent Vascular Events in HIV REPRIEVE is the first large-scale randomized clinical research trial to test a strategy for heart disease prevention among people living with HIV. Specifically, REPRIEVE will test whether a daily dose of a statin (pitavastatin) reduces the risk of heart disease among people living with HIV.
CTN+ Researchers are the backbone of the Network through generating ideas, collaborating on new initiatives, conducting research, and sharing their knowledge.
Explore Our NetworkInterested in joining the CTN+? We’re always on the lookout for new members to answer the most pressing research questions of today, while anticipating the questions of tomorrow.
Learn More